Ennov, a Paris, France-based global provider of regulatory, quality, and clinical software solutions for life sciences and healthcare companies, has secured strategic growth investment.
Investors
The investment round was led by Bregal Sagemount, with participation from Ardian.
Bregal Sagemount is a growth-focused private capital firm with $11 billion in cumulative capital raised. The firm provides flexible capital and strategic support to market-leading companies in high-growth sectors across a wide range of transaction types. Bregal Sagemount has invested in more than 90 companies across various sectors, including software, data and information services, financial technology and services, digital infrastructure, healthcare IT, and business and consumer services. The firm has offices in New York and Palo Alto.
Ennov Use of Funds
The company will use the funding to support its expansion through AI innovation, accelerated global go-to-market initiatives, and the scaling of its product offerings.
About Ennov
Ennov is a global provider of end-to-end regulatory, quality, clinical, and pharmacovigilance software solutions for life sciences and healthcare organizations. Founded in Paris more than 25 years ago, the company offers a unified compliance platform that centralizes content and data management across regulatory, quality, commercial, clinical, and safety operations. Ennov’s integrated architecture and AI-enabled platform help organizations streamline compliance processes, replace fragmented legacy systems, and improve operational efficiency. Headquartered in Paris, France, the company currently serves approximately 650 customers and more than 500,000 users across 30 countries.
Funding Details
Company: Ennov
Raised: Undisclosed
Round: Strategic Growth Investment
Funding Date: May 2026
Lead Investor: Bregal Sagemount
Additional Investor: Ardian
Company Website: https://en.ennov.com/
Software Category: Regulatory Compliance and Life Sciences Software
Source: https://www.businesswire.com/news/home/20260518090659/en/